One of the reasons that venture capital investment in biopharmaceutical companies is booming is because of mega-deals exceeding $100m in a single round – often at the Series A level – and the trend continues even in the lazy, hazy days of summer.
This year's biopharma VC total is on track to beat the 2017 total even before the end of the third quarter, especially with big rounds like Gossamer Bio Inc.'s recent $230m Series B. Big money is flowing ex-US as well, with China-based firms bringing in astonishing amounts of money, such as Ascentage Pharma Group Corp. Ltd. in Rockville, Md. and Hong Kong with a $150m Series C round. And then Alector Inc